Time-action profiles of novel premixed preparations of insulin lispro and NPL insulin

被引:90
作者
Heise, T
Weyer, C
Serwas, A
Heinrichs, S
Osinga, J
Roach, P
Woodworth, J
Gudat, U
Heinemann, L
机构
[1] Heinrich Heine Univ, Klin Stoffwechselkrankheiten & Ernahrung, Dept Metab Dis & Nutr, WHO Collaborating Ctr Diabet, D-40001 Dusseldorf, Germany
[2] Eli Lilly & Co, Indianapolis, IN 46285 USA
[3] Lilly Deutschland, Bad Homburg, Germany
关键词
D O I
10.2337/diacare.21.5.800
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE -To study the pharmacodynamic properties of three premixed formulations of the rapid-acting insulin analog insulin lispro and its protamine-retarded preparation, neutral protamine lispro (NPL) insulin. RESEARCH DESIGN AND METHODS -In this open, single-center, euglycemic glucose clamp study, 30 healthy volunteers (12 women, 18 men) aged 27 +/- 2 years (mean I SD), whose BMI was 23.0 +/- 2.3 kg/m(2), received subcutaneous injections of 0.3 U/kg body wt of insulin mixture (high-mixture 75/25, mid-mixture 50/50, or low-mixture 25/75 insulin lispro/NPL insulin), insulin lispro, or NPL insulin on one of the five study days in randomized order. Glucose infusion rates were determined over a period of 24 h after administration. RESULTS -Maximal metabolic activity decreased after subcutaneous injection of. the mixtures with lower insulin lispro content; however, the time point of maximal and of early half-maximal metabolic activity was comparable among the three mixtures. Higher proportions of insulin lispro resulted in higher values for area under the curve within the first 360 min after injection and a more rapid decline to late half-maximal activity Serum insulin concentrations showed a similar pattern. CONCLUSIONS -This study shows that the pharmacodynamic and pharmacokinetic properties of insulin lispro are preserved in stable mixtures with NPL insulin.
引用
收藏
页码:800 / 803
页数:4
相关论文
共 11 条
[1]   FITTING NONLINEAR-REGRESSION MODELS WITH CORRELATED ERRORS TO INDIVIDUAL PHARMACODYNAMIC DATA USING SAS SOFTWARE [J].
BENDER, R ;
HEINEMANN, L .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1995, 23 (01) :87-100
[2]   PHYSIOLOGICAL IMPORTANCE OF DEFICIENCY IN EARLY PRANDIAL INSULIN-SECRETION IN NON-INSULIN-DEPENDENT DIABETES [J].
BRUCE, DG ;
CHISHOLM, DJ ;
STORLIEN, LH ;
KRAEGEN, EW .
DIABETES, 1988, 37 (06) :736-744
[3]  
DeFelippis M.R., 1996, DIABETES S2, V45, p74A
[4]   Immunologic effects of insulin lispro [Lys (B28), Pro (B29) human insulin] in IDDM and NIDDM patients previously treated with insulin [J].
Fineberg, NS ;
Fineberg, SE ;
Anderson, JH ;
Birkett, MA ;
Gibson, RG ;
Hufferd, S .
DIABETES, 1996, 45 (12) :1750-1754
[5]  
Heinemann L, 1996, DIABETIC MED, V13, P683, DOI 10.1002/(SICI)1096-9136(199607)13:7<683::AID-DIA144>3.0.CO
[6]  
2-1
[7]   ACTION PROFILE OF THE RAPID ACTING INSULIN ANALOG - HUMAN INSULIN B28ASP [J].
HEINEMANN, L ;
HEISE, T ;
JORGENSEN, LN ;
STARKE, AAR .
DIABETIC MEDICINE, 1993, 10 (06) :535-539
[8]   [LYS(B28), PRO(B29)]-HUMAN INSULIN - A RAPIDLY ABSORBED ANALOG OF HUMAN INSULIN [J].
HOWEY, DC ;
BOWSHER, RR ;
BRUNELLE, RL ;
WOODWORTH, JR .
DIABETES, 1994, 43 (03) :396-402
[9]  
Radziuk J. R., 1996, Diabetologia, V39, pA224
[10]   Effects of the short-acting insulin analog [Lys(B28),Pro(B29)] on postprandial blood glucose control in IDDM [J].
Torlone, E ;
Pampanelli, S ;
Lalli, C ;
DelSindaco, P ;
DiVincenzo, A ;
Rambotti, AM ;
Modarelli, F ;
Epifano, L ;
Kassi, G ;
Perriello, G ;
Brunetti, P ;
Bolli, G .
DIABETES CARE, 1996, 19 (09) :945-952